Eculizumab use in severe HELLP syndrome with thrombotic microangiopathy and liver damage: a case report

Preeclampsia complicates 2–8% of pregnancies worldwide. HELLP syndrome is often considered a severe form of preeclampsia but can also present independently. These two conditions may have serious long-term consequences to the fetus and the mother, such as preterm birth or permanent organ damage to the mother. Growing evidence suggests that part of patients suffering from severe preeclampsia/HELLP present also TMA-type disease and may significantly benefit of new specific anti-complement medication to prevent organ damage. 41-year-old primigravida presented severe preeclampsia and HELLP at 34 gestational weeks, with signs of rapidly developing organ (liver) damage and thrombotic microangiopathy. High AST and ALT levels, necrosis in liver tissue, and poor portal vein blood flow in ultrasound indicated severe liver damage. Red cell fragmentation and thrombocytopenia indicated thrombotic microangiopathy and together with organ damage and signs of abnormal complement consumption led to the diagnosis of pregnancy-associated TMA. The patient was successfully treated with anti-complement medication (eculizumab) on the first postpartum day leading to rapid clinical recovery. Part of patients suffering from severe preeclampsia and HELLP present also thrombotic microangiopathy associated with disturbances in the complement function and may benefit from targeted anti-complement therapy.

Authors

Institutions

Publication Details

Journal
Journal of Medical Case Reports
Published
2026-11-14
DOI
https://doi.org/10.1186/s13256-026-06846-7
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Eculizumab use in severe HELLP syndrome with thrombotic microangiopathy and liver damage: a case report

Noora Korkalainen, Mikko Haapio, Jenni Heikkinen‐Eloranta, A. Inkeri Lokki
Journal of Medical Case Reports
Pregnancy and preeclampsia studies
article

Eculizumab use in severe HELLP syndrome with thrombotic microangiopathy and liver damage: a case report

Noora Korkalainen, Mikko Haapio, Jenni Heikkinen‐Eloranta, A. Inkeri Lokki
article en

Abstract

Preeclampsia complicates 2–8% of pregnancies worldwide. HELLP syndrome is often considered a severe form of preeclampsia but can also present independently. These two conditions may have serious long-term consequences to the fetus and the mother, such as preterm birth or permanent organ damage to the mother. Growing evidence suggests that part of patients suffering from severe preeclampsia/HELLP present also TMA-type disease and may significantly benefit of new specific anti-complement medication to prevent organ damage. 41-year-old primigravida presented severe preeclampsia and HELLP at 34 gestational weeks, with signs of rapidly developing organ (liver) damage and thrombotic microangiopathy. High AST and ALT levels, necrosis in liver tissue, and poor portal vein blood flow in ultrasound indicated severe liver damage. Red cell fragmentation and thrombocytopenia indicated thrombotic microangiopathy and together with organ damage and signs of abnormal complement consumption led to the diagnosis of pregnancy-associated TMA. The patient was successfully treated with anti-complement medication (eculizumab) on the first postpartum day leading to rapid clinical recovery. Part of patients suffering from severe preeclampsia and HELLP present also thrombotic microangiopathy associated with disturbances in the complement function and may benefit from targeted anti-complement therapy.

Journal of Medical Case Reports
University of Helsinki (FI), Helsinki University Hospital (FI)
Good health and well-being
Pregnancy and preeclampsia studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon